Patents by Inventor Shaopei Cai
Shaopei Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11021467Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: June 1, 2021Assignee: Gilead Sciences, Inc.Inventors: Shaopei Cai, Zhimin Du, Musong Kim, Jennifer A. Loyer-Drew, Devan Naduthambi, Leena Patel, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 10092563Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: October 9, 2018Assignee: Gilead Sciences, Inc.Inventors: Shaopei Cai, Zhimin Du, Joshua Kaplan, Jennifer A. Loyer-Drew, Devan Naduthambi, Barton W. Phillips, Gary Phillips, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361054Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Shaopei Cai, Zhimin Du, Joshua Kaplan, Jennifer A. Loyer-Drew, Devan Naduthambi, Barton W. Phillips, Gary Phillips, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361068Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Shaopei Cai, Zhimin Du, Musong Kim, Jennifer A. Loyer-Drew, Devan Naduthambi, Leena Patel, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES
Publication number: 20140303182Abstract: A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined hereinType: ApplicationFiled: March 17, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy Machajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus Okhamate, Marc S. Tesconi -
Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties
Publication number: 20130338171Abstract: A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined hereinType: ApplicationFiled: August 1, 2013Publication date: December 19, 2013Applicant: Novartis AGInventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy Machajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus Okhamafe, Marc S. Tesconi -
Patent number: 8450490Abstract: This invention provides compounds of the formula: wherein X is wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.Type: GrantFiled: September 14, 2012Date of Patent: May 28, 2013Assignee: Gilead Sciences, Inc.Inventors: William R. Baker, Shaopei Cai, Joshua Aaron Kaplan, Musong Kim, Gary Phillips, Lafe J. Purvis, II, Marcin Stasiak, Kirk L. Stevens, Josh Van Veldhuizen
-
Patent number: 8394829Abstract: Provided are compounds of Formula I: wherein X is: R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.Type: GrantFiled: May 9, 2011Date of Patent: March 12, 2013Assignee: Gilead Sciences, Inc.Inventors: William R. Baker, Shaopei Cai, Joshua Aaron Kaplan, Musong Kim, Jennifer Alissa Loyer-Drew, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Marcin Stasiak, Kirk K. Stevens, Josh Van Veldhuizen
-
Patent number: 8367829Abstract: This invention provides compounds of the formula: wherein X is wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.Type: GrantFiled: May 9, 2011Date of Patent: February 5, 2013Assignee: Gilead Sciences, Inc.Inventors: William R. Baker, Shaopei Cai, Joshua Aaron Kaplan, Musong Kim, Gary Phillips, Lafe J. Purvis, II, Marcin Stasiak, Kirk L. Stevens, Josh Van Veldhuizen
-
Publication number: 20130018050Abstract: This invention provides compounds of the formula: wherein X is wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Applicant: Gilead Sciences, Inc.Inventors: WILLIAM R. BAKER, Shaopei Cai, Joshua Aaron Kaplan, Musong Kim, Gary Phillips, Lafe J. Purvis, II, Marcin Stasiak, Kirk L. Stevens, Josh Van Veldhuizen
-
PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES
Publication number: 20130018058Abstract: A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined hereinType: ApplicationFiled: December 2, 2011Publication date: January 17, 2013Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy Machajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus O. Okhamafe, Marc S. Tesconi -
Publication number: 20130012504Abstract: Provided are compounds of Formula I: R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Gilead Sciences, IncInventors: William R. Baker, Shaopei Cai, Joshua Aaron Kaplan, Musong Kim, Jennifer Alissa Loyer-Drew, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Marcin Stasiak, Kirk L. Stevens, Josh Van Veldhuizen
-
Publication number: 20120277434Abstract: A method of synthesizing a substituted or unsubstituted 4-amino-3-benzimidazolyl quinolinone compound includes reacting a first compound having the formula I with a second compound having the formula II in a suitable solvent in the presence of a sodium or potassium salt of a base.Type: ApplicationFiled: July 2, 2012Publication date: November 1, 2012Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy MacHajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus O. Okhamafe, Marc S. Tesconi
-
Publication number: 20110275622Abstract: Provided are compounds of Formula I: wherein X is: R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicant: Gilead Sciences, Inc.Inventors: William R. Baker, Shaopei Cai, Joshua Aaron Kaplan, Musong Kim, Jennifer Alissa Loyer-Drew, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Marcin Stasiak, Kirk L. Stevens, Josh Van Veldhuizen
-
Publication number: 20110275623Abstract: This invention provides compounds of the formula: wherein X is wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicant: GILEAD SCIENCES, INC.Inventors: WILLIAM R. BAKER, SHAOPEI CAI, JOSHUA AARON KAPLAN, MUSONG KIM, GARY PHILLIPS, LAFE J. PURVIS, II, MARCIN STASIAK, KIRK L. STEVENS, JOSH VAN VELDHUIZEN
-
Patent number: 7825132Abstract: Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.Type: GrantFiled: November 5, 2004Date of Patent: November 2, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Carla C. Heise, Timothy D. Machajewski, David Ryckman, Xiao Shang, Marion Wiesmann, Shuguang Zhu
-
PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES
Publication number: 20090181979Abstract: A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined hereinType: ApplicationFiled: March 4, 2009Publication date: July 16, 2009Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy Machajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus O. Okhamafe, Marc S. Tesconi -
Publication number: 20050261307Abstract: Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.Type: ApplicationFiled: November 5, 2004Publication date: November 24, 2005Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Carla Heise, Timothy Machajewski, David Ryckman, Xiao Shang, Marion Wiesmann, Shuguang Zhu
-
Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
Publication number: 20050209247Abstract: A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined hereinType: ApplicationFiled: November 5, 2004Publication date: September 22, 2005Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy Machajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus Okhamafe, Marc Tesconi -
Publication number: 20050137399Abstract: A method of synthesizing a substituted or unsubstituted 4-amino-3-benzimidazolyl quinolinone compound includes reacting a first compound having the formula I with a second compound having the formula II in a suitable solvent in the presence of a sodium or potassium salt of a base.Type: ApplicationFiled: November 5, 2004Publication date: June 23, 2005Inventors: Shaopei Cai, Joyce Chou, Eric Harwood, Timothy Machajewski, David Ryckman, Xiao Shang, Shuguang Zhu, Augustus Okhamafe, Marc Tesconi